<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht003536.v1" study_id="phs000637.v1" participant_set="1" date_created="Mon Oct 21 12:33:10 2013"><variable id="phv00195880.v1"><name>SUBJECT ID</name><description>De-identified subject identifier</description><type>string</type></variable><variable id="phv00195881.v1"><name>Protocol</name><description>Children's Oncology Group P9904 and P9905 protocols. See Ramsey LB, et. Al. Blool 121(6):898-904, 2013 (PMID:23233662) for details.</description><type>string</type></variable><variable id="phv00195882.v1"><name>Treatment arm</name><description>Treatment arms in COG P9904/P9905 protocols.</description><type>string</type></variable><variable id="phv00195883.v1"><name>infusion</name><description>Methotrexate 4-hour infusion of a 2g/m2 dose or 24 hour infusion of a 1g/m2 dose</description><type>string</type></variable><variable id="phv00195884.v1"><name>average methotrexate clearance</name><description>Methotrexate clearance averaged over multiple courses for each patient</description><type>decimal</type><unit>mL/min/m2</unit><logical_min>59.07</logical_min><logical_max>299.16</logical_max></variable><variable id="phv00195885.v1"><name>Adjusted methotrexate clearance</name><description>Methotrexate clearance adjusted for protocol, treatment arm, infusion, gender, genetically determined race; mean clearance among patient population was normalized to zero.</description><type>decimal</type><unit>mL/min/m2</unit><logical_min>62.83</logical_min><logical_max>317.01</logical_max></variable><variable id="phv00195886.v1"><name>gender</name><description>Male or female</description><type>string</type></variable><variable id="phv00195887.v1"><name>genetically determined Race</name><description>Race genetcially determined using STRUCTURE with genome-wide mapping array</description><type>string</type></variable></data_table>
